DOVER, DE, UNITED STATES, January 15, 2026 /EINPresswire.com/ -- The safety of parenteral medicines and medical devices ...

NINGBO, ZHEJIANG PROVINCE, CHINA, January 21, 2026 /EINPresswire.com/ -- In recent years, the global life science ...

China quietly became biotech’s back-office, from molecule synthesis and clinical trials to novel drug licensing. Now the ...

The "Protein Engineering for Pharmaceutical Biotechnology Training Course (Jan 21st - Jan 22nd, 2026)" training has been added to ResearchAndMarkets.com's offering. Enhance your knowledge in protein ...

In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million ...

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.

During the first six months of this year, the pharmaceutical-biotech industry completed construction on a total of 31 new plants and research centers across North America During the first six months ...

The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation ...

In our final batch of Changing Faces columns for 2025, we’re detailing a flurry of senior leadership appointments in recent ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) stands ...

Healthcare stocks rallied in 2025, breaking a two-year slump as investors chased steadier rates, better valuations, and improving earnings. The problem: mid-single-digit gains still lagged tech, ...